Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.54 USD | -2.48% | +4.12% | -38.54% |
05-01 | Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer | CI |
03-21 | Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.54% | 72.5M | - | ||
+26.15% | 681B | C+ | ||
+21.85% | 556B | B | ||
-5.15% | 361B | C+ | ||
+17.16% | 325B | B- | ||
+4.94% | 285B | C+ | ||
+13.68% | 235B | B+ | ||
+3.65% | 199B | B- | ||
-11.12% | 189B | A+ | ||
-4.22% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DERM Stock
- Ratings Journey Medical Corporation